Medical Condition News

RSS

Skin cancer does not discriminate between skin colors

Do you have darker skin? If so, skin cancer might not be top of mind as a significant health threat, but beware – just because your skin is darker does not mean you are immune to skin cancer.

15 Jun 2012

Dyax to discontinue ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today the decision to discontinue the Company's Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema based upon the results of an interim analysis.

15 Jun 2012

Sanovas receives U.S. patent allowance for microsurgical lung cancer technology

Sanovas, Inc., a medical technology company focused on developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its first patent relating to systems and methods for the removal of unwanted biological material, such as tissue growths and tumors, in hard-to-reach bodily cavities.

15 Jun 2012

Single gene forms common link between diabetes and Alzheimer's

In recent years it became clear that people with diabetes face an ominous prospect - a far greater risk of developing Alzheimer's disease. Now researchers at The City College of New York (CCNY) have shed light on one reason why. Biology Professor Chris Li and her colleagues have discovered that a single gene forms a common link between the two diseases.

15 Jun 2012

MRF announces achievement of myelin repair Phase 1 trial for MS

The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation's goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.

15 Jun 2012

Study examines link between soft drink intake and risk of obesity in Canadian children

Most children and youth who consume soft drinks and other sweetened beverages, such as fruit punch and lemonade, are not at any higher risk for obesity than their peers who drink healthy beverages, says a new study published in the October issue of Applied Physiology, Nutrition, and Metabolism.

15 Jun 2012

High-efficiency oxygen inhaler from Dehaier

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that the Company has co-developed its "High-Efficiency Oxygen Inhaler" with Dr. Ding Jianzhang of Beijing Haidian Hospital, which is expected to begin selling in the third quarter of 2012 in mainland China.

15 Jun 2012

Dietitians now have access to simple genetic test kit from Nutrigenomix

The one-size-fits-all approach to nutritional counselling includes basic advice to eat more whole grains and cut back on sodium. While this guidance is certainly appropriate, it doesn't take into account that these universal nutrition recommendations are not equally useful for every person.

15 Jun 2012

Dexcom G4 system receives CE Mark approval

Dexcom, Inc. today announced that it has received CE Mark approval for its fourth generation continuous glucose monitoring system, the Dexcom G4 system, enabling commercialization of the Dexcom G4 system in the European Union and the countries in Asia and Latin America that recognize the CE Mark.

15 Jun 2012

Hay fever vaccine shows efficacy in phase IIa trial

A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.

14 Jun 2012

European launch of technology for quantitative assessment of Parkinson’s disease symptoms from Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they are launching the latest version of their medical device technology for assessing Parkinson’s disease next week at the Movement Disorders Society Congress in Dublin, Ireland.

14 Jun 2012

Antibody that blocks programmed cell death benefits cancer patients

A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1).

14 Jun 2012

Minimally invasive procedure to treat high blood pressure

A radically different approach to treating high blood pressure – using a minimally invasive procedure – is being evaluated as part of a Pivotal Phase III 90-site national trial that includes The Carl H. and Edyth Lindner Center for Research and Education at The Christ Hospital.

14 Jun 2012

New scientific findings in anticoagulation for stroke prevention

New scientific findings in anticoagulation for stroke prevention are paving the way for updates to the European Society of Cardiology (ESC) Guidelines for the management of atrial fibrillation.

14 Jun 2012

IBMT linked with positive structural changes in brain connectivity

A Texas Tech University scientist studying the Chinese mindfulness meditation known as integrative body-mind training (IBMT) said he and other researchers have confirmed and expanded on changes in structural efficiency of white matter in the brain that can be related to positive behavioral changes in subjects practicing the technique for a month and a minimum of 11 hours total.

14 Jun 2012

Scientists discover one of the most important cellular mechanisms behind meningioma

Johns Hopkins researchers say they have discovered one of the most important cellular mechanisms driving the growth and progression of meningioma, the most common form of brain and spinal cord tumor. A report on the discovery, published in the journal Molecular Cancer Research, could lead the way to the discovery of better drugs to attack these crippling tumors, the scientists say.

14 Jun 2012

African-American women with low SES more likely to develop obesity

Socioeconomic status across one's lifetime is related to weight gain and risk of obesity in African American women, according to a new study led by researchers from the Slone Epidemiology Center at Boston University. These findings currently appear online in the journal Ethnicity & Disease.

14 Jun 2012

Western-style diets may increase risk of inflammatory bowel disease

Certain saturated fats that are common in the modern Western diet can initiate a chain of events leading to complex immune disorders such as inflammatory bowel diseases (IBD) in people with a genetic predisposition, according to a study to be published early online in the journal Nature.

14 Jun 2012

Alpha-myosin triggers development of autoimmunity after heart attack

After people with type 1 diabetes have a heart attack, their long-term chance of suffering even more heart damage skyrockets. But the reason has long puzzled scientists. Now researchers at Joslin Diabetes Center have identified the misstep that sparks this runaway chronic damage and a promising way to block it.

14 Jun 2012

AB Science announces results from masitinib phase 2 study on MS

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treatment of progressive multiple sclerosis.

14 Jun 2012